You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Exact Sciences shares are falling sharply on worries that demand for its colon cancer-screening test will fall shy of predictions.
Investors took off exposure to Exact Sciences (EXAS -1.00%) in September ahead of a key update to colon cancer screening and that decision appears to have been the right one given that guidelines announced this month failed to include Exact Sciences' Cologuard.
In the following slideshow, you'll learn why this update to guidelines was important for Exact Sciences and the risks that its investors continue to face.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
